Maximum quantity allowed is 999
Please select the quantity
CAS RN: 391210-10-9 | Product Number: P2897
PD 0325901
×
![]()
×
Purity: >97.0%(T)(HPLC)
Synonyms:
- (R)-N-(2,3-Dihydroxypropoxy)-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
- N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 10MG |
$100.00
|
7 | 0 | It can be shipped in about 2 weeks after ordering |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | P2897 |
| Purity / Analysis Method | >97.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__6H__1__4F__3IN__2O__4 = 482.20 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Frozen (<0°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| CAS RN | 391210-10-9 |
| Reaxys Registry Number | 11343179 |
| MDL Number | MFCD08435926 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 97.0 area% |
| Purity(Volumetric Analysis) | min. 97.0 % |
| Melting point | 120.0 to 124.0 °C |
| Specific rotation | -2.0 to -3.5 deg(C=0.1, Methanol) |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 123 °C |
GHS
Related Laws:
Transport Information:
| H.S.code* | 2928.00-000 |
Application
PD 0325901: An Orally Active, Selective and Non-ATP-Competitive MEK (MAPKK) Inhibitor
The mitogen-activated protein kinase (MAPK) signaling pathway is involved in numerous cellular processes, including cell growth and differentiation. Phosphorylation of MAPK by MEK (MAPKK) leads to activation of this pathway, and is often overactive in some cancers. PD 0325901 is an orally active, selective and non-ATP-competitive MEK inhibitor that suppresses the phosphorylation of MAPK. In recent years, PD 0325901 has been investigated as a treatment for neurofibromatosis type1 (NF1). (The product is for research purpose only.)
References
- Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration
- The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
- Road to PD0325901 and beyond: The MEK Inhibitor Quest (a review)
- Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.